REBECCA Real-world Early BrEast CanCer mAnagement

AstraZeneca

Status: Enrolling

Conditions: Breast Cancer

Study type: Observational

Funder types: Industry

Identifiers

NCT06856343

D0817R00068

Details and patient eligibility

About

This is a French observational, national, multicenter prospective cohort study of patients with HER2-negative eBC treated with olaparib at their physician's discretion.

Full description

The purpose to this observational study is to evaluate the rate of completion of adjuvant Olaparib treatment for HER2-negative early breast cancer patients in France.

Enrollment: 126 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Male or female aged ≥ 18 years
• Patient diagnosed with HER2-negative eBC
• Patient about to be initiated with adjuvant Olaparib at their physician's discretion
• Patient has been informed and does not object to participation in the study.

Exclusion criteria

• Patient not consenting to participate.
• Patients included in the Early Access Program